Anthony Hagen
Advertisement
Articles by Anthony Hagen
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
Advertisement
Latest Updated Articles
Conference Coverage: European Hematology Association 2021 Virtual CongressPublished: August 17th 2021 | Updated:
- For Staying Power, Diabetes Interventions May Need a Hands-on Element
Published: January 21st 2015 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
4
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
5
